

wherein:

R^1 and R^2 are substituents on the A ring and are, independently, $-\text{SO}_2\text{NR}^7_2$, $-\text{C}(\text{O})\text{NR}^7_2$, $-\text{NR}^7\text{SO}_2\text{R}^7$, $-\text{NR}^7\text{C}(\text{O})\text{R}^7$, $-\text{SO}_2\text{OR}^7$, $-\text{C}(\text{O})\text{OR}^7$, $-\text{OSO}_2\text{R}^7$, or $-\text{OC}(\text{O})\text{R}^7$,

R^3 and R^4 are, independently, hydrogen or lower alkyl, or R^3 and R^4 together are $-(\text{CH}_2)_2-$, $-(\text{CH}_2)_3-$, or $-(\text{CH}_2)_4-$,

R^5 and R^6 are, independently, hydrogen, lower alkyl, substituted lower alkyl, cyano, halo, nitro, $-\text{SR}^8$, $-\text{C}(\text{O})\text{R}^8$, $-\text{SO}_2\text{OR}^8$, $-\text{OSO}_2\text{R}^8$, $-\text{SO}_2\text{NR}^8_2$, $-\text{NR}^8\text{SO}_2\text{R}^8$, $-\text{OC}(\text{O})\text{R}^8$, $-\text{C}(\text{O})\text{OR}^8$, $-\text{C}(\text{O})\text{NR}^8_2$, $-\text{NR}^8\text{C}(\text{O})\text{R}^8$, $-\text{OR}^8$, or $-\text{NR}^8_2$,

each R^7 and R^8 is, independently, hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, aryl(lower)alkyl, substituted aryl(lower)alkyl, heteroaryl(lower)alkyl, substituted heteroaryl-(lower)alkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl,

each Y is, independently, alkyl, substituted alkyl, cyano, halo, nitro, $-\text{SR}^9$, $-\text{OR}^9$, or $-\text{NR}^9_2$, where each R^9 is independently hydrogen, lower alkyl, or substituted lower alkyl,

each x is, independently, 0, 1 or 2, and

the urea linker connects a carbon which is designated c with a carbon which is designated d,

or a pharmaceutically acceptable salt thereof, optionally in the form of a single stereoisomer or mixture of stereoisomers thereof.

REMARKS

Entry of this amendment is respectfully requested. No new matter is added by the amendment as the amended claim 3 is supported by the text of WO 00/71506 at page 16, lines 6-9. This PCT publication is incorporated by reference into this application (see page 16, lines 10 and 16 of this application) and so is available to support the amendment. The US equivalent of the PCT publication is US Patent No. 6,458,998 (cited in the Office Action), and the corresponding text is seen at column 10, lines 15-18. The compound scope of the claim is that of Claim 1 of US Patent No. 6,458,998.

Claims 1-20 are in this application, no claims having been canceled or added, and claim 3 having been amended by this amendment. Claims 1-20 were subject to a restriction requirement, and Group I and the compound of claim 18 were elected. Claims 3-5 were rejected under 35 USC 112, ¶2, and for obviousness-type double patenting. These rejections are respectfully traversed.